Transcell Biologics secures funding from IAN & Quantiphi

Bio-tech company Transcell Biologics has raised an undisclosed amount of investment from Boston-based  Quantiphi and IAN Group.

The proceeds will be used for expanding the client base and implementation of Digital Animal Replacement Technology (DART) as an enterprise solution for the global bio and pharmaceutical industry, Transcell Biologics said in a press release.

Launched in 2009 by Subadra Dravida, Transcell Biologics specializes in maximizing stem cell yield while retaining pluripotency and functionality and also offers a proprietary process and has diversified its applications for stem cell technologies.

According to the Hyderabad-based company, DART provides animal-free testing methods, fusing human MicroPhysiological Systems (hMPS) technology with AI/ML embedded in silico platform configurations to streamline and automate the bioassay processes producing statistically compliant reports. The solution is designed to effectively test safety and efficacy concerns surrounding drugs and vaccines meant for human consumption.

Transcell Biologics says that implementation of DART has gained significant traction in Indian markets, with biopharmaceutical companies adopting its enterprise solution in their high-impact programs. The company intends to expand its client base in the USA, Europe, and Japan.